ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,393.80
0.85%
S&P ASX All Technology
3,840.60
-1.02%
Brent Oil
74.65
0.00%
US Dollar vs AUD
1.53846
0.06%
Bitcoin
98,666.74
-0.37%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. OSE Immunotherapeutics (OSE) Share Price

OSE Immunotherapeutics

OSE Immunotherapeutics (OSE)

EU
8.89
0.21
(2.42%)
Closed 24 November 3:30AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
8.89
Bid
8.85
Offer
9.00
Volume
132,937
8.60 Day's Range 9.05
3.115 52 Week Range 11.58
Market Cap
193.516M
Previous Close
8.68
Open
8.74
Last Trade
250
@
8.89
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
232,014
Shares Outstanding
21,767,777
Dividend Yield
-
PE Ratio
-8.41
Earnings Per Share (EPS)
-1.06
Revenue
2.23M
Net Profit
-23M

About OSE Immunotherapeutics

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
www.ose-immuno.com
Headquarters
Nantes, Loire-atlantique, Fra
Founded
-
OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 8.68 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 3.115 € to 11.58 €.

OSE Immunotherapeutics currently has 21,767,777 shares in issue. The market capitalisation of OSE Immunotherapeutics is 188.94 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -8.41.

Ask ADVFN Intelligence (AI)

OSE Latest News

More News

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article...

05 November 2024
UK Regulatory

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis OSE...

04 November 2024
UK Regulatory

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique

OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Étude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la...

04 November 2024
UK Regulatory

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis...

04 November 2024
GlobeNewswire Inc.

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index NANTES, France, October 17, 6:00pm CET - OSE...

18 October 2024
UK Regulatory

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine...

18 October 2024
GlobeNewswire Inc.

OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré

OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré OSE...

18 October 2024
UK Regulatory

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital al Nantes, le 2 octobre 2024 – En application de l’article L. 233-8 II du Code de commerce et de...

03 October 2024
UK Regulatory

OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées

OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le point sur ses avancées OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et fait le...

27 September 2024
UK Regulatory

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new...

27 September 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-2.841530054649.159.298.551302118.8474436DE
4-1.21-11.980198019810.111.588.551916869.93884583DE
120.8911.125811.586.552320148.92532609DE
261.114.12066752257.7911.585.372006798.04610128DE
524.3595.81497797364.5411.583.1151664386.97041962DE
156-0.05-0.5592841163318.9412.282.7051073366.46160763DE
2605.26144.9035812673.6315.452.705996297.40435DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLAAHAmatheon Agri Holding NV
0.02 €
(100.00%)
5k
GNROGeNeuro SA
0.0768 €
(25.49%)
200
BIDSGascogne DS
0.005 €
(25.00%)
150.51k
ALSAFSAFE
0.11 €
(23.73%)
39.98k
ALKKOKKO International SA
0.112 €
(21.21%)
4.13M
ALIMOGroupimo
0.189 €
(-40.94%)
392
MLUMGUmalis Group
1.30 €
(-31.22%)
1.71k
MLNMAMiguet Et Associes
0.075 €
(-24.62%)
1.72k
MLSEQSequa Petroleum NV
0.008 €
(-20.00%)
23k
VACBSPierre & Vacances
0.05 €
(-15.25%)
35.99k
BCPBanco Comercial Portugues SA
0.4446 €
(-0.49%)
69.24M
ALNEVNeovacs
0.0002 €
(0.00%)
41.4M
ALCYBCybergun
0.0001 €
(0.00%)
30.32M
INGAING Groep NV
14.652 €
(-1.16%)
14.06M
ACACredit Agricole SA
13.05 €
(-1.66%)
8.06M

Discussion

View Full Feed
Konaploinks Konaploinks 2 minutes ago
IonQ Investor Updates © 2024 IONQ
Recent
Announcements
25 IonQ Investor Updates
IonQ Investor Updates © 2024 IONQIonQ Investor Updates26 © 2024 IONQ
IonQ Signs Definitive Agreement to
Acquire the Operating Assets of Qubitekk
Transaction will significa
IONQ
Bountiful_Harvest Bountiful_Harvest 2 minutes ago
Gold surges for a fifth day in a row, its longest winning streak since April, and after rising 1.7% back over $2700 it is once again just shy of all time highs.

zerohedge@zerohedge
https://pbs.twimg.com/media/GdCn8RHX0AAKwCW?format=jpg&name=medium
GLD
ddls ddls 3 minutes ago
2005 this got to 60 cents a share. BIEL'S-NONE!😎

"Let's see how high our beloved BIEL get's"
BIEL
ssc ssc 3 minutes ago
Apparently the sketched head and "the other dickran" have stopped talking to you. Now it's a chatbot lmao).Quite the new story you are cooking up here with your chatbot chum and all the things Ntephe "couldn't" say . Shell deal, erhc as agent for Shell, Gabon enterprises and yet no word about any
ERHE
sekander sekander 3 minutes ago
If Bessent is good enough for Ackman, that's good enough for me.
Let's see what kind of bump we get on Monday.
FNMA
Watts Watt Watts Watt 5 minutes ago
You say, "More questions than answers".

Is this something new?

The only thing unquestionable about LQMT is the lunacy of the people who post here daily.
LQMT
ErnieBilco ErnieBilco 5 minutes ago
This will lose at least 3 zeros once Musk preps his 1st flight to Mars.
I expect it to be the ride of a lifetime and put me into retirement.
Patience and faith
ELONUSD
glenn1919 glenn1919 5 minutes ago
LUNR.......................................https://stockcharts.com/h-sc/ui?s=LUNR&p=W&b=5&g=0&id=p86431144783
LUNR
Konaploinks Konaploinks 7 minutes ago
This is huge news!
IonQ Investor Updates © 2024 IONQIonQ Investor Updates27 © 2024 IONQ
IonQ Announces a Collaboration with
AstraZeneca
IonQ to create a new quantum application development center in
collaboration with AstraZeneca. IonQ will be leveraging the power
IONQ
glenn1919 glenn1919 9 minutes ago
VUZI.............................https://stockcharts.com/h-sc/ui?s=VUZI&p=W&b=5&g=0&id=p86431144783
VUZI
Ruffy Capital Ruffy Capital 9 minutes ago
10-Q looks VERY interesting gents. Net profit Q3.

Margin expansion of 11% compared to Q3Y23, cost of revenue is flat on increased volume, which also implies operating efficienies are improving which will drop down to the gross line over the coming quarters.

Growth in HE
BWMG
JFR161162 JFR161162 9 minutes ago
Approval will lead to an higher stock price and this will lead to a takeover.

NWBO
dstock07734 dstock07734 10 minutes ago
Congrats on being all in. How long have you been holding?
NWBO
fredscott36 fredscott36 10 minutes ago
......NOT OUR LIBOR CASE, but related...........and will impact our case....................appears to me that nearly all interested parties are opposing a motion for summary judgement, filed and requested by........the city of Baltimore.........?????...........the FDIC, imo, is riding both sides of
ColdDarkHole ColdDarkHole 10 minutes ago
LMAO everyone says that-- "do you own DD". Do all the DD in the world. All the minnows and whales that chose to throw money into this hole are in the same boat here. This is speculative penny investing with a massive risk no matter how much the crowd says "de-risked" or "shovel ready". Give me
NB
hvacfarmer hvacfarmer 10 minutes ago
So what exchange is GDVM uplisting to is what I would really like to know? I wasn't aware they were trying to do that which explains all the continued silence we are getting and will continue to get until that is completed.
GDVM
lovethatgreen lovethatgreen 11 minutes ago
If the filings were legit this would be in dollars now
But it's not bid was 6 cents on Friday

There's a reason for that
BLFR
weedtrader420 weedtrader420 11 minutes ago
Doesn’t matter what crypto coin you buy everyone is going up SUKU XRP
XRPUSD
glenn1919 glenn1919 11 minutes ago
PDYN..............................https://stockcharts.com/h-sc/ui?s=PDYN&p=W&b=5&g=0&id=p86431144783
PDYN
TheFirm TheFirm 13 minutes ago
some of you are on drugs or have an inability to learn or comprehend... here are FACTS. not FANTASY. For example, when you leave a store with a power ball ticket, you have a chance to win $400 million... but the fact is you should not call your boss up and quit and curse him out. here are FACTS i
NSAV
Bountiful_Harvest Bountiful_Harvest 13 minutes ago
Rising wedge in play on descending volume. Money flow and momentum descending.
The Great Martis@great_martis - Nvidia Update keeping it simple.

Money flow and momentum descending.

140 goes and its lights out.

Guess what happens next ?
https:
NVDA
quester614 quester614 13 minutes ago
Are you sure of that. We know that Cameron Cox became the owner of FUTL after Aegea Inc failed. Here are 2 different companies that tie Cox and Biza from 2015. Cox is also on the XERI board. Henry Biza was also owner of Xeriant SRO & Movychem SRO.
Duffy and Crew have been working together fo
FUTL XERI

Your Recent History

EU
OSE
OSE Immunotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved